Literature DB >> 23296790

The MPTP/probenecid model of progressive Parkinson's disease.

Anna R Carta1, Ezio Carboni, Saturnino Spiga.   

Abstract

Parkinson's disease (PD) is characterized by a progressive degeneration of dopamine (DA) neurons and a chronic loss of motor functions. The investigation of progressive degenerative mechanisms and possible neuroprotective approaches for PD depends upon the development of an experimental animal model that reproduces the neuropathology observed in humans. This chapter describes the generation of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid (MPTPp) chronic mouse model of PD. This model displays key features of PD, including impairment of motor and olfactory functions associated with partial loss of tyrosine hydroxylase-positive neurons and DA levels in the brain. The MPTPp mouse model provides an important tool for the study of mechanisms contributing to the pathological dysfunction of PD at the cellular and whole animal level.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23296790     DOI: 10.1007/978-1-62703-251-3_17

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  7 in total

1.  MPTP-induced executive dysfunction is associated with altered prefrontal serotonergic function.

Authors:  Panchanan Maiti; Laura C Gregg; Michael P McDonald
Journal:  Behav Brain Res       Date:  2015-09-21       Impact factor: 3.332

Review 2.  CRISPR-Cas9-Based Technology and Its Relevance to Gene Editing in Parkinson's Disease.

Authors:  Mujeeb Ur Rahman; Muhammad Bilal; Junaid Ali Shah; Ajeet Kaushik; Pierre-Louis Teissedre; Małgorzata Kujawska
Journal:  Pharmaceutics       Date:  2022-06-13       Impact factor: 6.525

3.  Calpain mediated expansion of CD4+ cytotoxic T cells in rodent models of Parkinson's disease.

Authors:  Azizul Haque; Supriti Samantaray; Varduhi H Knaryan; Mollie Capone; Azim Hossain; Denise Matzelle; Raghavendar Chandran; Donald C Shields; Ariana Q Farrand; Heather A Boger; Naren L Banik
Journal:  Exp Neurol       Date:  2020-04-14       Impact factor: 5.330

4.  Neuroprotective Effect of Riboflavin Producing Lactic Acid Bacteria in Parkinsonian Models.

Authors:  Jean Guy LeBlanc; Alejandra de Moreno de LeBlanc; Daiana Perez Visñuk; María Del Milagro Teran; Graciela Savoy de Giori
Journal:  Neurochem Res       Date:  2022-02-03       Impact factor: 3.996

5.  Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease.

Authors:  Mária Baranyi; Pier Francesca Porceddu; Flóra Gölöncsér; Szabina Kulcsár; Lilla Otrokocsi; Ágnes Kittel; Annalisa Pinna; Lucia Frau; Paul B Huleatt; Mui-Ling Khoo; Christina L L Chai; Petra Dunkel; Peter Mátyus; Micaela Morelli; Beáta Sperlágh
Journal:  Mol Neurodegener       Date:  2016-01-13       Impact factor: 14.195

6.  Oral administration of Proteus mirabilis damages dopaminergic neurons and motor functions in mice.

Authors:  Jin Gyu Choi; Namkwon Kim; In Gyoung Ju; Hyeyoon Eo; Su-Min Lim; Se-Eun Jang; Dong-Hyun Kim; Myung Sook Oh
Journal:  Sci Rep       Date:  2018-01-19       Impact factor: 4.379

Review 7.  Animal Models for Parkinson's Disease Research: Trends in the 2000s.

Authors:  Kyohei Kin; Takao Yasuhara; Masahiro Kameda; Isao Date
Journal:  Int J Mol Sci       Date:  2019-10-30       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.